Price, Not Safety, Most Likely To Limit Avastin Use In Breast Cancer – JPMorgan Physician Survey
This article was originally published in The Pink Sheet Daily
Long-term revenue upside for drug in all indications could be as much as $6.5 billion by 2012, says JPMorgan analyst Geoffrey Meacham.
You may also be interested in...
FDA’s breast-cancer decision not a universal surprise, and there’s still risk in RIBBON-1.
Accelerated approval wants more clinical proof.
Though not registrational, study could bolster NDA package.